Compare Ginkgo Bioworks Holdings Inc (DNA) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Teradyne, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.11 (market cap $590.53M), while Teradyne, Inc. trades at $337.59 (market cap $55.30B). The key difference: Teradyne, Inc. is far larger — about 93.6× Ginkgo Bioworks Holdings Inc's market cap, and Teradyne, Inc. pays a 0.15% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | TER | |
|---|---|---|
Market Cap | $590.53M | $55.30B |
Sector | Health | Technology |
52-Week High | $16.14 | $483.84 |
52-Week Low | $5.48 | $90.15 |
Enterprise Value | $627.78M | $55.13B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Teradyne (TER) trades at $341.11, down 5.14% over 24 hours, with a bearish technical signal. The stock shows strong fundamentals with three consecutive quarterly earnings beats and robust profitability margins. Recent news highlights AI-driven demand boosting semiconductor testing revenue, positioning TER as a key player in robotics and AI infrastructure. Cash flow trends indicate consistent operational strength despite negative net cash flow from aggressive investing activities.
Outlook remains positive with a consensus price target of $453.60, implying 33% upside. Risks include high valuation multiples and semiconductor cycle volatility. Analyst sentiment is strongly bullish with 64.5% buy ratings, supported by expanding AI and data center markets driving long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
